Key result
Cardiac-specific VEGFB overexpression lowered coronary lipoprotein lipase activity, limited cardiac lipid metabolite accumulation, and augmented cardiac insulin action in rat hearts.
Why the study?
Does cardiac-specific VEGFB overexpression reduce lipoprotein lipase activity and improve insulin action in rat hearts?
Does cardiac-specific VEGFB overexpression reduce lipoprotein lipase activity and improve insulin action in rat hearts?
VEGFB overexpression in rat hearts lowers coronary LPL and improves insulin action, suggesting potential cardioprotective effects in metabolic disorders like diabetes.
Answers are grounded in this paper and cite their sources.
May warrant VEGFB investigation in diabetic cardiomyopathy; leaves open its therapeutic relevance pending human data.
In hearts overexpressing vascular endothelial growth factor B (VEGFB), besides its known angiogenic response, multiple regulatory mechanisms lowered coronary LPL. This was accompanied by limited cardiac lipid metabolite accumulation with an augmentation of cardiac insulin action. Our data for the first time links VEGFB to coronary LPL in regulation of cardiac metabolism. VEGFB may be cardioprotective in metabolic disorders like diabetes.
No takes yet. Share an insight, caveat, or question.
Shang et al. (2021) studied this question. Cardiac-specific VEGFB overexpression was evaluated on Coronary LPL activity, cardiac lipid metabolite accumulation, and cardiac insulin action. Cardiac-specific VEGFB overexpression lowered coronary lipoprotein lipase activity, limited cardiac lipid metabolite accumulation, and augmented cardiac insulin action in rat hearts.
Synapse has enriched 10 related papers. Consider them for comparative context: